New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia (ALL)

On October 13, 2017 Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorization for lyophilized ONCASPAR (pegaspargase), as a component of antineoplastic combination therapy in acute lymphoblastic leukemia (ALL) in pediatric patients from birth to 18 years, and in adult patients. Lyophilized ONCASPAR is a freeze-dried formulation of ONCASPAR (Press release, Shire, OCT 13, 2017, View Source [SID1234520886]). The liquid form of ONCASPAR is currently approved for the same indication in ALL, and is part of the pediatric standard therapy in ALL in many European countries.1 The CHMP’s positive opinion will be submitted to the European Commission (EC), which is responsible for granting marketing authorizations for medicines in the EU.

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells and is characterized by an overproduction and accumulation of lymphoblasts, immature white blood cells. ALL is the most common type (~75%) of cancer among children diagnosed with leukemia.2 ALL can be curable within certain pediatric patient populations, with a 5-year survival rate of more than 90% in children treated with regimens including ONCASPAR.3,4,5,

“Lyophilized ONCASPAR builds on more than a decade of data and research with liquid ONCASPAR, and with no change in dosing regimen, it offers a three-times longer shelf life,” said Howard B. Mayer, M.D., SVP and ad-interim Head, Global Research and Development, Shire. “Prolonging shelf life to 24 months for this critically-important therapy facilitates management of product inventory by enabling greater flexibility and longer-term planning. Once approved, with the extended shelf life of lyophilized ONCASPAR, we also hope to improve access to the medicine for ALL patients in countries currently not offering liquid ONCASPAR.”

Lyophilized ONCASPAR works the same way as the liquid formulation by rapidly depleting serum L-asparagine levels and interfering with protein synthesis, thereby depriving lymphoblasts of asparaginase and resulting in cell death. That is why asparaginase is a critical component of the treatment regimen for ALL patients as it is a proven approach to inducing leukemic cell death.4,6,7,8,9,10,11,

About Lyophilized ONCASPAR
Lyophilized ONCASPAR builds on more than a decade of data and research with liquid ONCASPAR, a pegylated asparaginase. The positive opinion is based on analytical and nonclinical studies, which demonstrate that the lyophilized formulation of ONCASPAR is comparable to the liquid formulation. Once reconstituted, lyophilized ONCASPAR demonstrates similar pharmacokinetic (PK)/pharmacodynamics (PD) to liquid ONCASPAR.1 The new lyophilized formulation offers no change in dosing regimen but a longer shelf life that is three times that of the liquid formation.1

About ONCASPAR
In Europe, ONCASPAR is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukemia (ALL) in pediatric patients from birth to 18 years, and adult patients.

ONCASPAR can be given by intramuscular injection or intravenous infusion. For smaller volumes of ONCASPAR, the preferred route of administration is intramuscular. When ONCASPAR is given by intramuscular injection the volume injected at one site should not exceed 2 ml in children and adolescents and 3 ml in adults. If higher volume is given, the dose should be divided and given at several injection sites. Intravenous infusion of ONCASPAR is usually given over a period of 1 to 2 hours in 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution. The diluted solution of ONCASPAR can be given together with an already-running infusion of either sodium chloride 9 mg/ml or 5% glucose. Do not infuse other medicinal products through the same intravenous line during administration of ONCASPAR.

Safety Information
ONCASPAR is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients, in patients with severe hepatic impairment, and in patients with a history of serious thrombosis, pancreatitis, or serious haemorrhagic events with prior L-asparaginase therapy.

Anaphylaxis or serious allergic reactions can occur; therefore, patients should be observed for 1 hour after administration having resuscitation equipment ready. Discontinue ONCASPAR in patients with serious allergic reactions. There have been reports of adverse reactions of pancreatitis. If pancreatitis is suspected ONCASPAR should be discontinued. ONCASPAR should also be discontinued in patients with serious thrombotic events.

Combination therapy with ONCASPAR can result in hepatic toxicity and central nervous system toxicity. Appropriate monitoring should be performed for liver impairment, blood and urine glucose levels as well as serum amylase for early signs of inflammation of the pancreas.

The very common adverse reactions reported in clinical trial data and the post-marketing experience of ONCASPAR in ALL patients include: hyperglycemia, pancreatitis, diarrhea, abdominal pain, nausea, vomiting, stomatitis, hypersensitivity, urticaria, anaphylactic reaction, weight decreased, decreased appetite, and rash.

Common adverse reactions include: febrile neutropenia, anemia, coagulopathy, hepatotoxicity, fatty liver, infections, sepsis, amylase increased, alanine aminotransferase increased, blood bilirubin increased, blood albumin decreased, neutrophil count decreased, platelet count decreased, activated partial thromboplastin time prolonged, prothrombin time prolonged, hypofibrinogenemia, hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, pain in extremities, seizure, peripheral motor neuropathy, syncope, posterior reversible leukoencephalopathy syndrome, hypoxia, and thrombosis.

OncoSec to Host Fourth Quarter and Year End Financial Results Conference Call on October 25, 2017

On October 13, 2017 OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, reported that the Company will host its fiscal fourth quarter and 2017 year-end financial results conference call on Wednesday, October 25th at 1:15 PM PT/4:15 PM ET (Press release, OncoSec Medical, OCT 13, 2017, View Source [SID1234520916]).

To access the audio broadcast, please dial (877) 731- 1960 and enter the conference ID number: 86520374. An archived version of the presentation will be available for 90 days on the “Investors” section of OncoSec’s website: View Source

Shire to announce third quarter 2017 results

On October 12, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), reported that it will announce third quarter 2017 earnings on Friday October 27, 2017 (Press release, Shire, OCT 12, 2017, View Source [SID1234520888]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on Shire’s Cancer Pipeline, book your free 1stOncology demo here.

Results press release will be issued at: 12:00 BST / 07:00 EDT
Investor conference call time: 14:00 BST / 09:00 EDT

Live conference call for investors:
Flemming Ornskov, MD, Chief Executive Officer, Jeff Poulton, Chief Financial Officer and Matt Walker, Head of Technical Operations will host the investor and analyst conference call at 9:00 EDT / 14:00 BST.

The details of the conference call are as follows:
UK dial in: 0808 237 0030 or 020 3139 4830
US dial in: 1 866 928 7517 or 1 718 873 9077
International Access Numbers: Click here
Password/Conf ID: 31097524#
Live Webcast: Click here

Replay:
A replay of the presentation will be available for two weeks by phone and by webcast for three months. Replay information can be found on the Investor Relations section of Shire’s website at View Source

For further information please contact:
Investor Relations
Ian Karp [email protected] +1 781 482 9018
Robert Coates [email protected] +44 203 5490874

Mirati Therapeutics’ Mocetinostat Included In Stand Up To Cancer’s Cutting-Edge Clinical Trial Initiative For NSCLC Patients

On October 12, 2017 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, reported that the Company has been included in the SU2C CatalystTM program, a cutting-edge research initiative led by Stand Up To Cancer (SU2C) designed to bring innovative cancer treatments to patients quickly through novel collaborations between industry and academia (Press release, Mirati, OCT 12, 2017, View Source [SID1234520918]).

A clinical trial research grant has been awarded to the Van Andel Research Institute (Grand Rapids, Michigan) to evaluate the potential of epigenetic agents to improve patient responses to immunotherapy in non-small cell lung cancer (NSCLC). The $2.5 million research grant will support a Phase 1/1b study combining Mirati’s mocetinostat, an orally-bioavailable, spectrum-selective Class 1 & IV HDAC inhibitor, guadecitabine, a DNA methyltransferase (DNMT) inhibitor from Astex, and pembrolizumab, a PD-1 checkpoint inhibitor from Merck (known as MSD outside the U.S. and Canada). The grant is provided by Merck, a SU2C Catalyst Founding Supporter.

“We are honored to participate in this ground-breaking trial with pembrolizumab and guadecitabine. The combination of immunotherapy with epigenetic agents such as mocetinostat has great potential to positively impact outcomes for patients with NSCLC,” said Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer. “The SU2C Catalyst program is an exceptional example of a collaboration designed to benefit cancer patients in an unprecedented way.”

The team is led by Stephen Baylin, M.D., and Matthew Hellmann, M.D. Dr. Baylin is the co-director of the Cancer Biology Division and associate director for research programs for Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as well as the co-leader of the VARI-SU2C Epigenetics Dream Team while Dr. Hellmann is an oncologist at Memorial Sloan Kettering Cancer Center in New York. Memorial Sloan Kettering will coordinate the trial with Dr. Hellmann as principal investigator.

“Despite the current and exciting advances with immune checkpoint therapy, many patients with NSCLC still do not receive benefit and this continues to be an extremely challenging disease. However, we remain optimistic that with continued research on the immune modulatory effects of epigenetic agents, the ability to test the hypothesis in trials like this, that these drugs combined with immune checkpoint therapy will contribute to improved ways to treat patients with NSCLC,” said Dr. Baylin.

The trial is now open and enrolled its first patient in August 2017. Additional information on the trial can be found at View Source For information on SU2C Catalyst and this project, visit SU2C.org.

Mirati is also conducting a Phase 2 study of mocetinostat in combination with durvalumab in NSCLC patients who have experienced progression of disease after treatment with checkpoint inhibitor therapy. Patients are stratified into two cohorts based upon their best response to prior checkpoint therapy. Stage 1 of the study is currently enrolling nine patients in each cohort; one cohort has already met the prespecified criteria for expansion into stage 2 with at least one confirmed partial response. Mirati will provide an update on this study by the end of the year.

About Mocetinostat (MGCD103)
Mocetinostat (MGCD103) is an orally-bioavailable, spectrum-selective Class I & IV HDAC inhibitor. Class I HDAC inhibition of histone acetylation is predicted to enhance the recognition of tumor cells by anti-tumor T cells and reverse immunosuppressive factors in the tumor microenvironment. Epigenetic immunomodulation may enhance immune response to tumors, and ultimately improve patient response to immunotherapies. Mocetinostat is being studied in a Phase 2 trial as a combination therapy with durvalumab, targeting the programmed death ligand 1 (PD-L1) pathway, which has been implicated in advanced lung cancers.
Mirati retains worldwide rights to mocetinostat except for certain Asian territories where the program is partnered with Taiho.

ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology

On October 12, 2017 ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on developing gene and cell-based immunotherapies for cancer, reported that three abstracts highlighting data from the Company’s Ad-RTS-hIL-12 + veledimex program have been accepted for presentation at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO). The meeting will be held Nov (Press release, Ziopharm, OCT 12, 2017, View Source [SID1234520884]). 16 – 19 in San Francisco. Additional information will be available from the Society when all abstracts are released from embargo on Nov. 6.

Details for the SNO presentations with discussion are as follows:

E-Talk: A Phase 1 study of Ad-RTS-hIL-12 + veledimex in adult recurrent glioblastoma
Presenter: E. Antonio Chiocca, M.D., Ph.D.
Session Title: Adult Therapeutics
Date and Time: Saturday, Nov. 18, 5:32 — 5:36 p.m. PST
Abstract Code: ATIM-26

Oral Presentation: Controlled expression of IL-12 improves survival in glioma by activating the immune response in mice and humans
Presenter: John A. Barrett, Ph.D.
Session Title: Immunology — Preclinical and Clinical I
Date and Time: Sunday, Nov. 19, 9:15 – 9:20 a.m. PST
Abstract Code: IMMU-34

Oral Presentation: Controlled local expression of IL-12 as gene therapy concomitant with systemic chemotherapy improves survival in glioma
Presenter: John A. Barrett, Ph.D.
Session Title: Immunology — Preclinical and Clinical I
Date and Time: Sunday, Nov. 19, 10 – 10:05 a.m. PST
Abstract Code: IMMU-33

About Ad-RTS-hIL-12 plus Veledimex

ZIOPHARM is advancing Ad-RTS-hIL-12 plus veledimex as a gene therapy for glioblastoma. Ad-RTS-hIL-12 is an adenoviral vector administered via a single injection into the tumor and engineered to express hIL-12, a powerful cytokine that has demonstrated the potential to stimulate a targeted, anti-tumor immune response. The expression of hIL-12 is controlled and modulated with the RheoSwitch Therapeutic System (RTS) by the small molecule veledimex, an activator ligand which has been shown to cross the blood brain barrier. ZIOPHARM anticipates initiation of a pivotal trial for Ad-RTS-hIL-12 plus veledimex for the treatment of rGBM by the end of 2017. The Company also has initiated a Phase 1 study to evaluate the stereotactic administration of Ad-RTS-hIL-12 plus veledimex in adult patients with rGBM, and plans to initiate enrollment of adult patients with rGBM who will receive a single dose of Ad-RTS-hIL-12 plus veledimex in combination with a checkpoint inhibitor targeting programmed cell death protein 1 (PD-1) by the end of the year.